X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TTK HEALTHCARE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA TTK HEALTHCARE DISHMAN PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 25.1 22.9 109.4% View Chart
P/BV x 3.3 7.7 43.4% View Chart
Dividend Yield % 0.7 0.4 176.4%  

Financials

 DISHMAN PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TTK HEALTHCARE
Mar-14
DISHMAN PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs374663 56.4%   
Low Rs129399 32.3%   
Sales per share (Unadj.) Rs197.8535.6 36.9%  
Earnings per share (Unadj.) Rs21.215.9 133.0%  
Cash flow per share (Unadj.) Rs34.720.0 173.4%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.80.8 105.5%  
Book value per share (Unadj.) Rs179.9137.6 130.7%  
Shares outstanding (eoy) m80.697.77 1,038.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.0 128.3%   
Avg P/E ratio x11.933.3 35.6%  
P/CF ratio (eoy) x7.226.5 27.3%  
Price / Book Value ratio x1.43.9 36.2%  
Dividend payout %9.425.1 37.6%   
Avg Mkt Cap Rs m20,3064,127 492.0%   
No. of employees `0000.81.7 48.5%   
Total wages/salary Rs m5,355607 882.8%   
Avg. sales/employee Rs Th19,252.72,436.7 790.1%   
Avg. wages/employee Rs Th6,459.5355.2 1,818.8%   
Avg. net profit/employee Rs Th2,064.172.5 2,845.4%   
INCOME DATA
Net Sales Rs m15,9614,162 383.5%  
Other income Rs m26561 433.7%   
Total revenues Rs m16,2264,223 384.2%   
Gross profit Rs m4,103197 2,081.8%  
Depreciation Rs m1,09132 3,440.4%   
Interest Rs m94430 3,158.5%   
Profit before tax Rs m2,334197 1,186.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62473 856.6%   
Profit after tax Rs m1,711124 1,381.0%  
Gross profit margin %25.74.7 542.8%  
Effective tax rate %26.737.0 72.2%   
Net profit margin %10.73.0 360.1%  
BALANCE SHEET DATA
Current assets Rs m11,0181,629 676.5%   
Current liabilities Rs m9,5171,058 899.7%   
Net working cap to sales %9.413.7 68.6%  
Current ratio x1.21.5 75.2%  
Inventory Days Days11030 371.1%  
Debtors Days Days3534 103.7%  
Net fixed assets Rs m16,304556 2,930.8%   
Share capital Rs m16178 207.7%   
"Free" reserves Rs m12,907878 1,469.5%   
Net worth Rs m14,5161,069 1,357.5%   
Long term debt Rs m4,189159 2,639.8%   
Total assets Rs m29,8052,399 1,242.2%  
Interest coverage x3.57.6 45.8%   
Debt to equity ratio x0.30.1 194.5%  
Sales to assets ratio x0.51.7 30.9%   
Return on assets %8.96.4 139.0%  
Return on equity %11.811.6 101.7%  
Return on capital %17.518.5 95.0%  
Exports to sales %24.80.8 3,135.6%   
Imports to sales %3.71.4 266.7%   
Exports (fob) Rs m3,95633 12,024.9%   
Imports (cif) Rs m59658 1,022.8%   
Fx inflow Rs m4,95233 15,050.2%   
Fx outflow Rs m69763 1,102.7%   
Net fx Rs m4,255-30 -14,046.6%   
CASH FLOW
From Operations Rs m2,786127 2,200.9%  
From Investments Rs m-1,529-146 1,047.2%  
From Financial Activity Rs m-94122 -4,297.3%  
Net Cashflow Rs m3163 12,656.0%  

Share Holding

Indian Promoters % 61.4 65.4 93.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 3.7 100.0%  
FIIs % 12.7 5.2 244.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 25.8 85.7%  
Shareholders   46,261 12,723 363.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 43.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, TTK HEALTHCARE has posted a net profit of Rs 80 m (up 43.1% YoY). Sales on the other hand came in at Rs 1 bn (up 21.4% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS